10-K: IMAC Holdings, Inc. Closes Outpatient Clinics, Focuses on Strategic Alternatives in 2023

IMAC Holdings, Inc. ceased operations at all outpatient medical clinics and BackSpace locations by the end of 2023, shifting focus to strategic alternatives.

Summary

• IMAC Holdings, Inc. closed or sold all of its outpatient medical clinics and BackSpace locations by December 31, 2023.
• The company reported a net loss of $9.4 million for 2023, compared to a net loss of $18.3 million in 2022.
• Adjusted EBITDA was a loss of $3.8 million in 2023, compared to a loss of $7.8 million in 2022.
• The company incurred $2,000 in FDA related expenses for the year ended December 31, 2023 compared to $523,000 for the year ended December 31, 2022.
• IMAC experienced one-time expenses of $1.2 million in impairment loss related to intangible assets and a $2.3 million write-down of a note receivable.
• The company is exploring strategic alternatives, including a potential merger with Theralink Technologies, Inc.

Sentiment

Score: 2

Explanation: The document indicates a significant downturn in the company's operations, with clinic closures, substantial losses, and a going concern warning. The focus on strategic alternatives suggests a need for a major restructuring, which is not a positive sign for investors.

Positives

• The net loss decreased significantly from $18.3 million in 2022 to $9.4 million in 2023.
• Adjusted EBITDA improved from a loss of $7.8 million in 2022 to a loss of $3.8 million in 2023.
• FDA related expenses decreased substantially from $523,000 in 2022 to $2,000 in 2023.

Negatives

• All outpatient medical clinics and BackSpace locations were closed or sold by the end of 2023.
• The company experienced a $1.2 million impairment loss on intangible assets.
• A $2.3 million write-down of a note receivable was recorded.

Risks

• The company has a history of net losses and negative cash flow from operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on obtaining additional financing to support ongoing operations.
• The company may not be able to successfully complete the proposed merger with Theralink Technologies, Inc.
• The company faces risks related to potential changes in healthcare regulations and reimbursement policies.

Future Outlook

The company is focused on exploring strategic alternatives, including a potential merger with Theralink Technologies, Inc., while also evaluating other options for structuring the business combination.

Management Comments

• Management has been actively exploring various strategic alternatives since July 2022.
• Management has determined that the company's financial condition raises substantial doubt as to its ability to continue as a going concern.

Industry Context

The closure of IMAC's clinics reflects a challenging environment for outpatient medical service providers, particularly those focused on regenerative medicine, which often face reimbursement challenges and high operating costs. The company's strategic shift towards a merger or other alternatives is indicative of the need for consolidation and restructuring in the healthcare sector.

Comparison to Industry Standards

• The closure of all clinics and the focus on strategic alternatives is a significant departure from the typical growth trajectory of healthcare service providers.
• The company's financial performance, with substantial net losses and negative EBITDA, is below industry benchmarks for established healthcare companies.
• The company's decision to sell assets and discontinue operations is similar to other companies facing financial distress in the healthcare sector, such as those that have failed to achieve profitability or secure adequate funding.
• The company's focus on regenerative medicine, while innovative, has not translated into financial success, unlike some other companies that have successfully commercialized similar therapies.

Management Changes

Legal Proceedings

• The company is subject to ongoing audits by CMS and other third-party payers, which may result in recoupment of payments.

Related Party Transactions

• The company entered into a note payable with Edward S. Bredniak, a former director.
• The company paid The MOLO Agency, owned by a board member, for marketing services.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees have been impacted by the closure of clinics and staff reductions.
• Patients have been affected by the closure of clinics and the discontinuation of services.
• Creditors face uncertainty regarding the company's ability to repay debts.

Next Steps

• The company will continue to explore strategic alternatives, including the proposed merger with Theralink Technologies, Inc.
• The company will seek additional financing to support ongoing operations.
• The company will seek shareholder approval for the issuance of securities related to the merger and other transactions.

Key Dates

Keywords

IMAC Holdings, outpatient clinics, BackSpace, strategic alternatives, merger, Theralink Technologies, net loss, EBITDA, impairment loss, note receivable, FDA, going concern